Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. has filed Post-Effective Amendment No. 1 converting its earlier Form S-1 into a Form S-3 and keeping available for resale up to 1,397,184 common shares held by selling shareholders. The company states it will receive no proceeds from those resale transactions.
The prospectus incorporates the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and discloses that 39,362,109 common shares were outstanding as of March 17, 2026. The filing also summarizes the August 29, 2025 acquisition of Antev for approximately $2.97 million in cash plus 1,603,164 consideration shares and describes contractual staggered lock-up releases for the consideration shares.
Medicus Pharma Ltd. filed a post-effective amendment converting its prior Form S-1 into a Form S-3 and registering for resale up to 7,500,000 common shares by YA II PN, Ltd. under a standby equity purchase agreement (SEPA) dated February 10, 2025.
The prospectus states the registered shares consist of 105,840 Commitment Shares plus up to 7,394,160 shares that Medicus may elect to issue and sell to the Selling Shareholder, and that the company will not receive proceeds from resale. The SEPA contemplates up to $15.0 million of purchases (approximately $2.5 million remains available) and the company reported having issued 9,014,633 common shares to the Selling Shareholder for gross proceeds of approximately $12.5 million as of March 17, 2026.
Medicus Pharma Ltd. files a Post-Effective Amendment registering up to 3,245,595 common shares issuable from time to time upon the exercise of outstanding warrants (985,595 Public Warrants and 2,260,000 June 2030 Warrants).
The prospectus states the company would receive net proceeds from cash exercises of those warrants and cites March 17, 2026 and March 24, 2026
Medicus Pharma Ltd. registers up to 1,397,184 common shares via a prospectus supplement to its Form S-1, and this supplement incorporates the Form 10-K filed on March 25, 2026. The supplement updates the offering materials and amends the Prospectus effective November 14, 2025.
The Form 10-K included by reference summarizes Medicus’s operations, including completion of the Antev acquisition for approximately $2.97M plus 1,603,164 shares, clinical progress for D-MNA (Phase 2 topline results) and regulatory clearances and study-may-proceed letters for its Teverelix programs.
Medicus Pharma Ltd. amends its May 29, 2025 prospectus to register 2,260,000 common shares issuable upon the exercise of outstanding public warrants. The supplement attaches the company's Form 10-K and updates disclosures, including that the public warrants have an exercise price of $4.64 and expire on November 15, 2029. The filing cites last reported sales prices on March 24, 2026 of $0.49 per common share and $0.57 per Public Warrant, and states there were 39,362,109 common shares outstanding as of March 17, 2026. The Form 10-K (fiscal year ended December 31, 2025) also summarizes clinical-stage programs (SkinJect D-MNA and Antev/Teverelix), the August 29, 2025 acquisition of Antev, contingent milestone consideration arrangements, and recent regulatory interactions and topline Phase 2 D-MNA results.
Medicus Pharma Ltd. registers 1,115,500 common shares issuable upon the exercise of warrants under a prospectus supplement amending the April 10, 2025 prospectus.
The supplement attaches the Form 10-K for the fiscal year ended December 31, 2025 and updates related disclosures. The Public Warrants have an exercise price of $4.64 and an expiration date of November 15, 2029. The common shares and Public Warrants trade on Nasdaq under the symbols MDCX and MDCXW. Shares outstanding were 39,362,109 common shares as of March 17, 2026.
Medicus Pharma Ltd. registers up to 7,500,000 common shares via a prospectus supplement to its effective Registration Statement on Form S-1.
The supplement incorporates the Company’s Form 10-K filed March 25, 2026, and notes 39,362,109 common shares outstanding as of March 17, 2026. The Company’s common shares trade on Nasdaq under the symbol MDCX; the last reported sales price on March 24, 2026 was $0.49.
Medicus Pharma Ltd. is a clinical-stage biotech company developing two main assets: SkinJect’s doxorubicin-containing microneedle array (D‑MNA) for non‑melanoma skin cancers and Antev’s Teverelix, a long‑acting GnRH antagonist for advanced prostate cancer and acute urinary retention.
The company completed a reverse takeover of SkinJect in 2023, listed on Nasdaq in 2024, and voluntarily delisted from the TSX Venture Exchange in 2025. As of March 17, 2026, it had 39,362,109 common shares outstanding and a non‑affiliate market value of about $28.3 million as of June 30, 2025.
SkinJect’s Phase 1 trial met safety and secondary efficacy endpoints, and a 90‑patient Phase 2 study (SKNJCT‑003) in nodular BCC has completed enrollment, with topline data showing the 200 µg dose achieving 73% clinical and 40% histological clearance at Day 57. A UAE Phase 2 trial (SKNJCT‑004) is also underway.
In August 2025, Medicus acquired 98.6% of Antev for roughly $2.97 million in cash plus 1,603,164 shares, with up to $65 million in contingent FDA milestone payments. Teverelix holds composition and process patents out to 2039 and beyond, with FDA‑cleared Phase 2b programs in both advanced prostate cancer and acute urinary retention.
Medicus maintains extensive microneedle IP licensed from the University of Pittsburgh, global Teverelix patents, and several non‑binding collaborations, including with HelixNano on mRNA‑based vaccines and Reliant AI on AI‑driven clinical development. The company has 16 full‑time employees and qualifies as an emerging growth and smaller reporting company, allowing scaled U.S. disclosure requirements.